Related Experiment Videos
Evaluation of luteal support therapy in a randomized controlled study within a gamete intrafallopian transfer program
J L Yovich1, W R Edirisinghe, J M Cummins
1PIVET Medical Centre, Perth, Western Australia.
Fertility and Sterility
|January 1, 1991
Summary
Luteal support therapy significantly improved birth rates and ongoing implantation in women undergoing fertility treatments. Combined progesterone and human chorionic gonadotropin therapy showed the most promising results, especially for embryos with lower quality scores.
Area of Science:
- Reproductive Endocrinology
- Infertility Treatment
- Clinical Trials
Background:
- Luteal phase defect can negatively impact pregnancy success.
- Optimizing luteal support is crucial for assisted reproductive technologies.
- Previous studies show varied results on luteal support efficacy.
Purpose of the Study:
- To evaluate the efficacy of luteal support therapy on pregnancy and implantation rates.
- To assess the impact of progesterone and human chorionic gonadotropin (hCG) on fertility outcomes.
- To investigate the influence of embryo quality (E factor) on treatment effectiveness.
Main Methods:
- Randomized controlled trial with 207 women.
- Four treatment groups: placebo, progesterone, hCG, and combined therapy.
- Rigid selection criteria to minimize confounding variables.
- Mathematical modeling to analyze uterine receptivity and embryo quality interactions.
Main Results:
- Birth rates were significantly higher with luteal support (29.4%) compared to no treatment (11.8%).
- Ongoing implantation rates were significantly improved with luteal support (9.0% vs. 3.6%).
- Combined therapy showed a potential 2.5-fold increase in ongoing implantation for poorest quality embryos.
Conclusions:
- Luteal support therapy, particularly combined progesterone and hCG, enhances birth and ongoing implantation rates.
- The benefits of luteal support are more pronounced in cases with lower embryo quality.
- Further research with larger sample sizes is warranted to confirm pregnancy rate improvements.